GSK (GSK) announced that China’s National Medical Products Administration, NMPA, has approved a new indication for Trelegy Ellipta, fluticasone furoate / umeclidinium / vilanterol, for the treatment of patients with asthma aged 18 years and older, adding to its current license for use in patients with chronic obstructive pulmonary disease, COPD. The approval means that Trelegy Ellipta is the first and only single inhaler triple therapy, SITT, approved for the maintenance treatment of both respiratory conditions in the country. Approval was based on GSK’s CAPTAIN study which showed that in patients uncontrolled on inhaled corticosteroids/long-acting beta agonist, the additional bronchodilation provided by Trelegy Ellipta demonstrated significant improvements in lung function compared with fluticasone furoate / vilanterol.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK Halts Early-Stage Sickle Cell Study, Tweaking the Risk Profile of Its Rare Disease Pipeline
- Moderna Stock (MRNA) Hits a New 52-Week High — Can the Rally Last Through 2026?
- GSK and Alector Phase 3 Dementia Trial Ends Early: What Investors Need to Know
- Midday Fly By: Netflix and Warner amend deal, GSK to acquire Rapt
- GSK, Shionogi reach agreement with Pfizer for interest in ViiV Healthcare